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I
n recent years, the British Medical Jour-
nal published several papers apropos
the “parachute approach evidence-
based medicine” (1). In the original pro-
found article, Smith and Pell argued that
the parachute use to prevent death and
major trauma due to capital challenge is
clearly obvious, and there is no need for
randomized controlled trials (2). Al-
though this argument may hold true in
medicine for only few situations, waiting
for the results of randomized end point
trialsoftherapeuticinterventionscancost
hundred of lives under certain circum-
stances. If the science is good, we should
act before trials are performed using in-
termediate end points or “surrogates” as
therapeutic targets. Indeed, surrogate pa-
rameters have emerged as most helpful
tools for an evidence-based approach for
therapeutic decisions in cardiovascular
medicine.Theensuingarticleoutlinesthe
pro arguments that surrogates are most
acceptable targets for treating patients
with hypertension and diabetes.
ELIGIBILITY OF
SURROGATES— AccordingtoMer-
riamWebster’sdictionary,themeaningof
surrogateis“oneappointedtoactinplace
of another” and “one that serves as a sub-
stitute.” In the 2007 European Society of
Hypertension Guidelines (3), the word
“surrogate” is replaced by the wording
“intermediate end point,” thereby point-
ing to the fact that, in hypertensive dis-
ease, a surrogate in general reﬂects early
structural or functional changes of the
vascular, renal, or cardiac tissue due to
the presence of cardiovascular risk fac-
tors. More speciﬁcally, certain require-
ments for clinical use of organ damage
measuresshouldbefulﬁlledbeforeaclin-
ical parameter is considered an interme-
diate end point or surrogate for fatal or
nonfatal cardiovascular complications.
Theseeligibilitycriteriaareasfollows:the
surrogate must be a sensitive and com-
monmarkerofearlydamageincardiovas-
cular disease, should ideally be measured
noninvasively, should have a high repro-
ducibility (low between/within-observer
variability), the assessment must be
(worldwide) standardized, and evidence
of prognostic importance of the selected
surrogate parameter should be docu-
mentedinseveralpopulations.Moreover,
and most importantly, reduction of sur-
rogate parameters for organ damage
should be associated with improved car-
diovascular and renal prognosis as evi-
denced in more than one prospective
randomized clinical trial.
According to current guidelines and
practice by the authorities for drug ap-
proval (Europe, Middle East, and Africa
[EMEA],FoodandDrugAdministration),
the biomarkers (blood pressure, blood
glucose, and serum lipid concentrations)
are accepted as surrogates in the ﬁeld of
hypertension and diabetes. The justiﬁca-
tion for acceptance of these parameters
(all are more biomarkers than surrogate
parameters of organ damage measures) is
based on epidemiological evidence, doc-
umented pathogenetic links between
these biomarkers and cardiovascular
damage, and most salient, the evidence
that reduction of these biomarkers is as-
sociated with improved cardiovascular
prognosis and increased life expectancy.
The weakness of this concept, at least
from a clinical perspective, is that the ac-
curacyofindicatingincidentofcardiovas-
cular disease is poor. Overall, it has been
clearly shown that 2 mmHg reduction in
blood pressure is related to a 7% reduc-
tion of myocardial infarction and a 10%
reduction of stroke (4). Although this
ﬁnding is helpful from a general perspec-
tive,theprecision/accuracyastowhichof
the hypertensive patients proﬁt most
from blood pressure–lowering interven-
tionisinadequateanddoesnotfacilitatea
tailored therapeutic approach.
Therefore, the question arises whether
there are additional surrogates that can
more precisely predict the cardiac, renal, or
vascular prognosis of diabetic and hyper-
tensive patients.
SURROGATES OF
CARDIOVASCULAR-RENAL
DAMAGE— More than 15 years ago,
Dzau and Braunwald (5) introduced the
concept of the cardiovascular continuum
in medicine. Starting with the well-
known cardiovascular risk factors, such
as diabetes, hypertension, and hyperlip-
idemia, early functional and structural
changes in the renal and systemic vascu-
lature occur as evidenced by vascular and
endothelial dysfunction, atherosclerosis,
and vascular and cardiac remodeling. If
treatmentremainsinadequateforalonger
period, myocardial infarction and stroke
occur, ultimately leading to ventricular
dilatation, congestive heart failure, and
end-stage heart disease and eventually to
cardiac and cerebrovascular death. Re-
cently, we learned that parallel to the car-
diovascular continuum, a similar renal
continuum exists, starting with the same
cardiovascular risk factors and leading to
similar pathogenetic processes. Whereas
microalbuminuria and macroalbumin-
uria/proteinuria reﬂect the intermediate
stage of the renal continuum, decreased
renalfunctionandend-stagerenaldisease
are at the far end of the renal continuum.
A pivotal goal of treating cardiovascular-
renal disease is to prevent the progression
of the disease along the cardiovascular
andrenalscale.Identiﬁcationofsurrogate
parameters within this range would help
to specify the stage of cardiovascular-
renal damage in individual patients and,
therefore, provide the tool for individual-
ized treatment strategies. In other words,
the greater the cardiovascular and renal
damage, the more aggressive and persis-
tent the treatment strategy should be.
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have been carefully deﬁned (3). Several
measures of subclinical cardiovascular-
renal damage have been subsequently
identiﬁed,andscreeninghasbeenrecom-
mended for each hypertensive and dia-
betic patient. To identify early structural
changesoftheheart,leftventricularmass,
relative wall thickness as a parameter for
the concentric type of left ventricular hy-
pertrophy (LVH), and left atrial remodel-
ing were identiﬁed as surrogates fulﬁlling
all requirements of intermediate end
points(Fig.1).Forexample,LVHisaspe-
ciﬁc and sensitive marker of early hyper-
tensive heart disease and can easily be
detected by electrocardiography and
echocardiography (6). The assessment of
LVHisstandardizedandaccordingtosev-
eral prospective trials, it has been docu-
mented as a major cardiovascular risk
factor in the hypertensive, diabetic, and
general population of various ages, sex,
and ethnic origins. Furthermore, with
progressive increase of left ventricular
mass, the risk of cardiovascular events in-
creases in parallel (7). Accordingly, inti-
ma-mediathicknessofthecarotidarteries
serves as an excellent surrogate of car-
diovascular risk associated with carotid
artery disease (8). In the systemic circu-
lation, carotid-femoral pulse wave ve-
locity was found to have predictive
value for cardiovascular events in 12
studies comprising 13,000 subjects
with various cardiovascular disorders at
baseline (9).
The surrogate marker “increased al-
bumin excretion” does not only indicate
the development of chronic renal failure
and end-stage renal disease, but serves
also as an indicator for cardiovascular
prognosis (10). In the Losartan Interven-
tionforEndpointReductioninHyperten-
sion (LIFE) trial, increased albumin
excretion, even in the normal range (the
so-calledlow-gradealbuminuria),isasso-
ciated with increased cardiovascular
eventrate(11).Inthegeneralpopulation-
based PREVEND study, there was a pro-
gressivelyenhancedriskofcardiovascular
mortalitywithincreasedalbuminconcen-
tration in the spot urine (12). Thus, in-
creased urinary albumin excretion (low-
grade albuminuria, microalbuminuria,
and macroalbuminuria) fulﬁls all the re-
quirements of an ideal surrogate parame-
ter for renal and cardiovascular disease
(3). In particular, the simplicity of mea-
suring urinary albumin excretion from
the spot urine, as well as its high sensitiv-
ity and prognostic importance, has been
well evidenced in the last 5–10 years.
IMPROVED PROGNOSIS
RELATED TO REVERSAL OF
SURROGATE END POINTS—I t
isaprovenfactthatthereductionofblood
pressure, blood glucose, and serum LDL
cholesterol levels are associated with im-
proved cardiovascular, cerebrovascular,
and renal prognosis. Such evidence has
been documented in randomized con-
trolled clinical prospective trials and has
lead to the inclusion of these biomarkers
in therapeutic recommendation of vari-
ousinternationalguidelines(3).Likewise,
prospective trials using echocardiography
to diagnose LVH have consistently found
that regression of LVH results in a re-
duced cardiovascular event rate (13). In a
meta-analysis, the odds ratio was 0.41 in
favor of LVH regression as opposed to
LVH persistence. In the LIFE trial, regres-
sion of electrocardiographic evidence of
LVH led to a highly signiﬁcant reduction
of cardiovascular mortality, myocardial
infarction, stroke, and the composite end
point. This ﬁnding was signiﬁcant, since
evenafteradjustmentfortreatmenteffect,
baseline Framingham risk score, and
baseline and in-treatment systolic and di-
astolic blood pressure, the hazard ratio of
cardiovascular complications remained
signiﬁcantly reduced in favor of LVH re-
gression (14).
In addition to the prognostic data,
our pathogenetic understanding of hy-
pertensive disease supports the concept
that LVH is a valid surrogate for cardiac
organ damage at a stage when the struc-
tural and functional changes can be re-
versed (intermediate end point). Several
clinical studies have found that reduction
of LVH leads to improved myocardial
ischemia, improved systolic contractility,
and improved left ventricular ﬁlling, re-
duced incidence of atrial ﬁbrillation, and
ventricular arrhythmia (6). All these car-
diac impairments due to LVH predispose
to myocardial infarction, congestive heart
failure, thrombo-embolism, and cardiac
sudden death (6). Conversely, it can be
expected that reversal of these pathoge-
netic mechanisms result in improved
cardiovascular prognosis. Thus, it is
conceivable that also in the HOPE study,
i.e., in patients at high risk of cardiovas-
cular events, reduction of primary out-
come (cardiovascular death, myocardial
infarction,andstroke)wasdeterminedby
the changes in LVH (15).
To date, only a few, but nevertheless,
largeprospectivetrialshavesubstantiated
the notion that reduction of albuminuria
islinkedtoimprovedrenalandcardiovas-
cular prognosis. In the LIFE trial, com-
prising nearly 10,000 hypertensive
patients with LVH, reduction of urinary
albumin excretion within the ﬁrst year
(most occur even in the normoalbumin-
uricrange)hasbeenfoundtohavealower
incidence of the composite end point of
cardiovascular death, stroke, and myo-
cardial infarction (16).
Similarly, in a study analyzing mi-
croalbuminuria and tubular proteinuria
as risk predictors of cardiovascular mor-
bidityandmortalityinessentialhyperten-
sion (MARPLE study), it was found that
conversionofpathologicalalbuminuriato
normal-rangealbuminuriawasassociated
with a reduced cardio- and cerebrovascu-
lar morbidity and total mortality (17). In
Figure 1—Hypertensive heart disease: pathogenetic determinants of LVH (top), its pathogenetic
consequences (middle), and cardiovascular fatal and nonfatal events due to LVH (bottom).
Schmieder
care.diabetesjournals.org DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 S295the Reduction of Endpoints in NIDDM
with the Angiotensin II Antagonist Losar-
tan (RENAAL) trial, the treatment of hy-
pertensive patients with type 2 diabetes
and overt proteinuria by effective blood
pressure control with an angiotensin re-
ceptor blocker has been analyzed through-
out follow-up of 2.6 years. In this trial,
reduction of proteinuria of 30% was
highly signiﬁcant and associated with re-
ducedincidenceofrenalendpoints(mostly
renalreplacementtherapy)(18)and,inpar-
allel, to improved cardiovascular prognosis
with respect to the cardiovascular com-
bined end point, as well as to congestive
heart failure (19) (Fig. 2).
Thus, with respect to LVH and albu-
minuria, we have solid evidence that re-
duction of these surrogates is followed by
a lower incidence of cardiovascular and
renal complications.
THE VALUE OF
SURROGATES IN CLINICAL
PRACTICE— Identiﬁcation of surro-
gatesinclinicalpracticefacilitatesdiagno-
sis of organ damage at a stage when fatal
consequencescanbeavoidedbyadequate
treatment. Moreover, the stage within the
cardiovascular and renal continuum can
be identiﬁed for each individual patient
and, consequently, individualized treat-
mentstrategiesmaybeapplied.Thetreat-
ment of LVH should be preferably carried
out with calcium antagonists, ACE inhib-
itors, and/or angiotensin receptor block-
ers, since they have been found to be
superior to diuretics and -receptor
blockers in reducing LVH (20). It is of
interest that even after 5 years of treat-
ment, the signiﬁcant difference in regres-
sion of LVH persisted between the
treatment strategies with -receptor
blockers, as opposed to angiotensin re-
ceptor blockers (21). Accordingly, hyper-
tensive patients with diabetes and elevated
urinary albumin excretion should prefera-
bly be treated with ACE inhibitors and an-
giotensin receptor blockers (3). These
recommendationsarebasedonseveralclin-
ical trials and meta-analyses. The studies
uniformly demonstrated that the men-
tioned preferential drug classes have organ-
protective effects beyond those of their
effect on blood pressure alone.
The assessment of surrogates in long-
term treatment is a clinically helpful tool
to ensure the patient’s adherence to the
regimen. Reduction of albuminuria or
LVH after several months should be con-
veyed to the patient as an indicator of im-
proved structure and function in the
respective organ. Long-term adherence is
essential for the effectiveness of any treat-
ment strategy, and the measurement of
surrogates represents a tool for individu-
alized treatment approaches and helps to
improve the patient’s adherence. In con-
trast to the assessment of vascular risk
scores that represent a more general ap-
proach of risk assessment, identiﬁcation
of early organ damage along the cardio-
vascularandrenalcontinuumenablesthe
physician to use an individualized ap-
proach that is clearly preferential. This fa-
cilitates a tailored medication to treat to
the detected organ damage.
CONCLUSIONS— Only few clinical
parametersfulﬁlltherequirementsforac-
ceptance as a surrogate of organ damage
incardiovascularmedicine.Undoubtedly,
left ventricular hypertrophy, albuminuria,
and to a lesser extent, parameters of vascu-
lar stiffening (e.g., pulse wave velocity)
represent clinically helpful tools to ade-
quately diagnose hypertensive diabetic
patients and to modify their treatment on
an individual basis. Treatment of surro-
gates further represents helpful tools to
monitorthesuccessoftherapyandadher-
ence to the administered medication.
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